This journal is © The Royal Society of Chemistry 2024

Daratumumab (μg/mL)														
run	2.00		5.00		10.0		50.0		100		200		400	
	Con.	%RE	Con.	%RE	Con.	%RE	Con.	%RE	Con.	%RE	Con.	%RE	Con.	%RE
1	2.20	9.9	5.15	3	8.58	-14.2	51.5	3	97.4	-2.6	201	0.7	401	0.2
2	2.00	0.1	5.27	5.5	9.66	-3.4	50.6	1.1	94.0	-6	205	2.7	400	0
3	2.00	0.1	5.44	8.7	9.73	-2.7	49.1	-1.9	91.9	-8.1	207	3.3	402	0.6
Mean	2.07		5.29		9.32		50.4		94.5		204		401	
SD	0.114	-	0.144	-	0.644	-	1.233	-	2.762	-	2.723	-	1.126	-
%CV	5.5		2.7		6.9		2.4		2.9		1.3		0.3	
%REn	3.33		5.73		-6.83		0.73		-5.53		2.23		0.33	

Pembrolizumab (μg/mL)														
run	2.00		5.00		10.0		50.0		100		200		400	
	Con.	%RE	Con.	%RE	Con.	%RE	Con.	%RE	Con.	%RE	Con.	%RE	Con.	%RE
1	2.13	6.3	4.83	-3.5	10.0	0.1	50.3	0.5	97.6	-2.4	194	-3	408	2
2	2.39	19.6	5.57	11.3	8.78	-12.3	45.0	-9.9	85.9	-14.1	202	1.1	417	4.3
3	2.30	14.8	5.34	6.9	8.19	-18.1	43.2	-13.6	87.2	-12.8	200	-0.1	419	4.8
Mean	2.27		5.25		8.99		46.2		90.3		199		415	
SD	0.135	-	0.379	-	0.925	-	3.666	-	6.400	-	4.211	-	5.815	-
%CV	6.0		7.2		10.3		7.9		7.1		2.1		1.4	
%REn	13.63		4.93		-10.13		-7.73		-9.73		-0.63		3.73	